CRISPR/Cas9 genome editing technology significantly accelerated herpes simplex virus research. (Q52431840)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29691470%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

title

CRISPR/Cas9 genome editing technology significantly accelerated herpes simplex virus research (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29691470%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

0 references

0 references

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29691470%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Zhao Wu Ma

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29691470%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

author name string

Dong Wang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29691470%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Xian-Wang Wang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29691470%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Xiao-Chun Peng

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29691470%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Shi-Bao Song

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29691470%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Ying-Ying Wang

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29691470%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Lin Chen

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29691470%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Victoria W Xin

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29691470%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Yan-Ning Lyu

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29691470%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Jiafu Ji

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29691470%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Cheng-Bin Li

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29691470%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Hong-Wu Xin

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29691470%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

publication date

25 April 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29691470%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29691470%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29691470%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

page(s)

93-105

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29691470%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

issue

5-6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29691470%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/s41417-018-0016-3

24 March 2020

exact match

0 references

cites work

Gene therapy returns to centre stage

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

CRISPR-Cas systems for editing, regulating and targeting genomes

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

CRISPR/Cas9 for genome editing: progress, implications and challenges.

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Talimogene laherparepvec (T-VEC) as cancer immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Preclinical evaluation of herpes simplex virus armed with granulocyte-macrophage colony-stimulating factor in pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Identification of genes that are associated with DNA repeats in prokaryotes

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Genome editing. The new frontier of genome engineering with CRISPR-Cas9

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Highly active zinc-finger nucleases by extended modular assembly

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Modular system for the construction of zinc-finger libraries and proteins

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

High-frequency modification of plant genes using engineered zinc-finger nucleases

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Targeted genome editing across species using ZFNs and TALENs

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

A ligation-independent cloning technique for high-throughput assembly of transcription activator–like effector genes

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Iterative capped assembly: rapid and scalable synthesis of repeat-module DNA such as TAL effectors from individual monomers

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Structural Basis for Sequence-Specific Recognition of DNA by TAL Effectors

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Breaking the code of DNA binding specificity of TAL-type III effectors

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

A library of TAL effector nucleases spanning the human genome

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

1 reference

7 January 2021

Multiplex genome engineering using CRISPR/Cas systems

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

The CRISPRdb database and tools to display CRISPRs and to generate dictionaries of spacers and repeats

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

TALEN or Cas9 - rapid, efficient and specific choices for genome modifications

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies.

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

RNA-guided human genome engineering via Cas9

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

CRISPR-Cas9 nuclear dynamics and target recognition in living cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Inactivation of Cancer Mutations Utilizing CRISPR/Cas9.

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Continuous genetic recording with self-targeting CRISPR-Cas in human cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

RNA targeting with CRISPR-Cas13.

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Correction of β-thalassemia mutant by base editor in human embryos

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Enhanced proofreading governs CRISPR-Cas9 targeting accuracy

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Evolution and classification of the CRISPR-Cas systems

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Cas9 as a versatile tool for engineering biology

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Non-homologous end-joining for repairing I-SceI-induced DNA double strand breaks in human cells

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects.

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Chemical and Biophysical Modulation of Cas9 for Tunable Genome Engineering

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9.

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Unexpected mutations after CRISPR–Cas9 editing in vivo

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases.

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

DNA targeting specificity of RNA-guided Cas9 nucleases

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Herpes simplex virus infections

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Herpes simplex keratitis

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Herpes Virus Encephalitis in Adults: Current Knowledge and Old Myths

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Herpes simplex virus-1 evasion of CD8+ T cell accumulation contributes to viral encephalitis.

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Herpes Simplex Virus Establishment, Maintenance, and Reactivation: In Vitro Modeling of Latency

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Oncolytic virotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Viruses as anticancer drugs

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Oncolytic virus therapy using genetically engineered herpes simplex viruses

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Development and applications of a nasopharyngeal carcinoma Tet-Off cell line

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11.

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Use of recombinant adenovirus for metabolic engineering of mammalian cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

A marker-free system for highly efficient construction of vaccinia virus vectors using CRISPR Cas9.

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

CRISPR-Cas9 system-driven site-specific selection pressure on Herpes simplex virus genomes

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

The mutated tegument protein UL7 attenuates the virulence of herpes simplex virus 1 by reducing the modulation of α-4 gene transcription

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

CRISPR-Cas9 as a Powerful Tool for Efficient Creation of Oncolytic Viruses

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Targeting genomic rearrangements in tumor cells through Cas9-mediated insertion of a suicide gene

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Programmable RNA Tracking in Live Cells with CRISPR/Cas9.

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

High-efficiency targeted editing of large viral genomes by RNA-guided nucleases

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Engineering large viral DNA genomes using the CRISPR-Cas9 system

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage

1 reference

https://api.crossref.org/works/10.1038%2FS41417-018-0016-3

7 January 2021

10.1038/S41417-018-0016-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29691470%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

1 reference